SAB Biotherapeutics (SABS) Current Leases (2020 - 2025)
Historic Current Leases for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $837286.0.
- SAB Biotherapeutics' Current Leases rose 11753.79% to $837286.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $837286.0, marking a year-over-year increase of 11753.79%. This contributed to the annual value of $393430.0 for FY2024, which is 4127.44% down from last year.
- According to the latest figures from Q3 2025, SAB Biotherapeutics' Current Leases is $837286.0, which was up 11753.79% from $815064.0 recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Current Leases registered a high of $1.2 million during Q3 2022, and its lowest value of $384892.0 during Q3 2024.
- Its 5-year average for Current Leases is $728636.1, with a median of $607955.0 in 2023.
- Per our database at Business Quant, SAB Biotherapeutics' Current Leases crashed by 5703.88% in 2022 and then soared by 11753.79% in 2025.
- Quarter analysis of 5 years shows SAB Biotherapeutics' Current Leases stood at $1.1 million in 2021, then plummeted by 57.04% to $490794.0 in 2022, then skyrocketed by 36.5% to $669946.0 in 2023, then plummeted by 41.27% to $393430.0 in 2024, then skyrocketed by 112.82% to $837286.0 in 2025.
- Its Current Leases was $837286.0 in Q3 2025, compared to $815064.0 in Q2 2025 and $793360.0 in Q1 2025.